News
-
According to Novartis, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Seebri Breezhaler glycopyrronium/NVA237 DPI for the treatment of COPD. Novartis submitted the MAA in September 2011.… Read more . . .
-
Regency Therapeutics has announced the initiation of the 18-month AMPED (Acute Management of Pain from the Emergency Department) registry study to compare patient response to Sprix ketorolac tromethamine nasal spray used to treat pain in… Read more . . .
-
Alexza Pharmaceuticals says that it has resubmitted its NDA for Adasuve inhaled loxapine for the treatment of agitation in patients with bipolar disorder or schizophrenia; the company received a Complete Response Letter for the Adasuve… Read more . . .
-
PPD is currently looking to recruit a Scientist to be based in our cGMP Lab in Athlone, Ireland. The basic purpose of the Scientist role is to perform a variety of complex sample preparation and… Read more . . .
-
GlaxoSmithKline has acquired rights to several inhaled drug candidates manufactured using Liquidia Technologies’ PRINT (Particle Replication In Non-Wetting Templates) platform. The PRINT nanofabrication technology produces particles with narrow size distribution and any desired shape. According… Read more . . .
-
Particle design and dry powder inhalation specialist Hovione has announced that sales for the fiscal year that ended in March, 2012 increased to $180 million,a 24% increase over the previous year. In addition to inhalation… Read more . . .
-
Liquidia Technologies is seeking a talented technical leader to join the company’s pharmaceutical research and development efforts. Job description • Hands-on technical leadership role designing and developing novel particle-based product candidates • Develop and execute… Read more . . .
-
Liquidia Technologies, Research Triangle Park, NC, is seeking a talented individual to join the pharmaceutical development team. This role will support research programs through development and scale-up of clinical and commercial formulations for pharmaceutical products… Read more . . .
-
MicroDose Therapeutx and Moerae Matrix have agreed to collaborate on development of a dry powder inhaler, using MicroDose DPI technology to deliver Moerae’s MMI-0100 MK2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). There… Read more . . .
-
According to Bloomberg News, Merck plans to appeal a ruling by Judge Peter Sheridan of the US District Court for the District of New Jersey that Merck failed to prove its allegation that Apotex infringed… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.